Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2024-04-25 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first quarter of 2024 (Q1 2024). It contains detailed financial statements, including revenue breakdowns, EBITA, EPS, cash flow, and management commentary on performance. It is not a mere announcement (RPA) or a short earnings release (ER), as it provides substantive financial data and analysis for the interim period. Therefore, it is classified as an Interim / Quarterly Report. Q1 2024
2024-04-25 English
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
AGM Information Classification · 100% confidence The document explicitly states it is a "Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)". It details the date, time, location, and procedures for shareholder participation (in person and by postal voting). Furthermore, the proposed agenda items (items 1 through 21) cover standard AGM topics such as election of the chair, approval of the agenda, presentation of annual reports, discharge from liability, determination of director/auditor fees, and resolutions on remuneration and share issuance. This content perfectly matches the definition of AGM Information.
2024-04-04 English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)" which translates to "Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)". The text details the date, time, location, procedures for participation (in person or by postal vote), and the proposed agenda items for the meeting. Key agenda items include election of the chairman, approval of the agenda, election of board members and auditor, decisions on remuneration, and guidelines for executive compensation. This content is characteristic of a formal notice and materials distributed for an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document length is substantial (58,970 chars), confirming it is the full notice/material, not just a brief announcement (RPA/RNS).
2024-04-04 Swedish
Annual Report (ESEF) 2023
Annual Report (ESEF) Classification · 100% confidence FY 2023
2024-04-02 Swedish
Earnings Release 2023
Earnings Release Classification · 99% confidence The document is titled "Bokslutskommuniké för 2023" (Year-end report/Financial Statement Release for 2023) and contains detailed financial figures for the fourth quarter (Kv4) and the full year (Helår) 2023, including revenue, EBITA margins, EPS, and outlook for 2024. It includes a CEO statement and extensive financial tables. This structure is characteristic of an Earnings Release (ER) or a comprehensive Interim/Annual Report. Since it covers the full year ('Bokslutskommuniké' often implies the annual result, though it might precede the formal 10-K), and provides detailed performance analysis beyond just the initial highlights, it leans towards a comprehensive report. However, in many European contexts, the 'Bokslutskommuniké' is the official press release announcing the full-year results, which aligns best with the 'Earnings Release' (ER) definition, which covers periodical financial results (in this case, annual results). Given the depth, it could also be considered an Interim Report (IR) if the company typically uses this format for annual results instead of a 10-K equivalent, but 'ER' is the best fit for a results announcement document that is not the full statutory annual report (10-K). The document is very long (134k chars), suggesting it is more than just a brief release, but the content structure strongly suggests a formal results announcement/release. Q4 2023
2024-02-08 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the fourth quarter and full year 2023, containing detailed financial statements, revenue breakdowns, EBITA analysis, and management commentary. It is not a short announcement or a certification letter, but rather the substantive interim/quarterly report itself, providing actual financial data and performance analysis. Q4 2023
2024-02-08 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.